Dr. Douglas Loe

Leede Financial Inc.

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.

Recent Articles about Cardiol Therapeutics

Canadian Pharma Finds Promising Cardiovascular Breakthrough 08/08/2025

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock.

Analyst Says Biotech's Data Supports Advancement Into Phase III 11/19/2024

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.